RxDoctor Payments Data

Courtney Eure, PA

Medical · Martinsville, VANPI 1841689379

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 808 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 59 manufacturers, the largest accounting for just 17.4% — the pattern of someone who eats at a lot of different presentations. Among medical clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$12,303in general payments, 2019–2025

Across 808 payments — averaging $15.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • Otsuka America Pharmaceutical, Inc.$854
  • Pfizer$842
  • Lilly USA, LLC$678
  • AstraZeneca$492
  • plus $6K from 53 others

What the payments were for

  • Food & beverage$12,303100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)147$2,142
Novo Nordisk82$1,244
Otsuka America Pharmaceutical, Inc.52$854
Pfizer82$842
Lilly USA, LLC46$678
AstraZeneca(2 entities)25$492
Amgen33$486
GSK27$429
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC22$377
Lundbeck LLC24$353
Mylan Specialty L.p.16$299
Abbott15$272
Takeda Pharmaceuticals U.S.A., Inc.14$253
Merck17$249
Bayer15$247
Boehringer Ingelheim15$232
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)14$198
Currax Pharmaceuticals LLC12$189
Johnson & Johnson11$187
E.r. Squibb & Sons, L.L.C.11$167
Phathom Pharmaceuticals, Inc.9$162
Ardelyx, Inc.8$148
Ironwood Pharmaceuticals, Inc8$115
Astellas Pharma US Inc7$110
Aimmune Therapeutics, Inc.6$109
Nestle Healthcare Nutrition Inc.6$100
Sunovion Pharmaceuticals Inc.7$97
Eisai Inc.7$88
Vanda Pharmaceuticals Inc.4$88
Sanofi-aventis U.S. LLC6$80
Alkermes, Inc.4$79
Biohaven Pharmaceutical Holding Company Ltd.5$77
Esperion Therapeutics, Inc.4$68
Novartis4$66
Idorsia Pharmaceuticals US Inc4$61
Exact Sciences3$60
Biogen3$50
Xeris Pharmaceuticals, Inc.3$50
Biohaven Pharmaceuticals, Inc.2$46
Corium, LLC3$43
Gilead1$43
Dexcom, Inc.2$35
Impel Pharmaceuticals Inc.2$33
Lexicon Pharmaceuticals, Inc.2$31
ANI Pharmaceuticals, Inc.1$31
Phadia US Inc.2$30
Seqirus USA Inc2$29
Medtronic2$28
ARS Pharmaceuticals Operations, Inc.1$23
Verona Pharma, Inc.1$16
Organon1$16
Recordati_rare_diseases_inc.1$15
Axsome Therapeutics, Inc.1$15
Sanofi Pasteur Inc.1$14
Vifor Pharma, Inc.1$12
Kowa Pharmaceuticals America, Inc.1$12
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)1$11
Amarin Pharma, Inc.1$11
Metacel Pharmaceuticals LLC1$8

How this compares

$12,303 in reported general payments places this provider in the 95th percentile of 632 medical providers in Virginia.

See all medical providers in Virginia

Medicare billing

Part B allowed, 2024
$37,546
Medicare patients
188
Services billed
1,047

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide90$116,590
TrulicityDulaglutide93$91,996
JanuviaSitagliptin Phosphate69$73,853
MounjaroTirzepatide62$71,520
JardianceEmpagliflozin73$65,374
ZenpepLipase/Protease/Amylase11$58,509
EliquisApixaban70$55,680
LinzessLinaclotide55$38,070
MyrbetriqMirabegron42$30,883
VraylarCariprazine Hcl16$26,589
CreonLipase/Protease/Amylase20$25,946
FarxigaDapagliflozin Propanediol34$23,815
XareltoRivaroxaban34$23,507
Breo ElliptaFluticasone/Vilanterol48$19,303
Spiriva HandihalerTiotropium Bromide21$15,611

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$678$163,516155 claims
Novo NordiskOzempic$1,244$116,59090 claims
AbbVieLinzess, Vraylar, Creon$2,142$90,60591 claims
MerckJanuvia, Belsomra$249$84,02492 claims
Boehringer IngelheimJardiance, Combivent Respimat$232$70,65284 claims
PfizerEliquis, Premarin$842$60,70492 claims
Aimmune Therapeutics, Inc.Zenpep$109$58,50911 claims
GSKBreo Ellipta, Trelegy Ellipta, Shingrix$429$38,47993 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$492$37,15663 claims
Astellas Pharma US IncMyrbetriq$110$30,88342 claims
Johnson & JohnsonXarelto$187$23,50734 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 632 medical providers in Virginia.

Other medical in Martinsville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →